Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Abstract Text:

J Bernhard,D Zahrieh,J J Zhang,G Martinelli,R Basser,C ,J F Forbes,S Aebi,W Yeo,B ,M D Green,M Colleoni,R D Gelber,M Castiglione-Gertsch,K N Price,A Goldhirsch,A S Coates,J Bernhard,D Zahrieh,J J Zhang,G Martinelli,R Basser,C Hürny,J F Forbes,S Aebi,W Yeo,B Thürlimann,M D Green,M Colleoni,R D Gelber,M Castiglione-Gertsch,K N Price,A Goldhirsch,A S Coates, ,J Bernhard,D Zahrieh,J J Zhang,G Martinelli,R Basser,C ,J F Forbes,S Aebi,W Yeo,B ,M D Green,M Colleoni,R D Gelber,M Castiglione-Gertsch,K N Price,A Goldhirsch,A S Coates, ,

Quality of life (QL) is an important consideration when comparing adjuvant therapies for early breast cancer, especially if they differ substantially in toxicity. We evaluated QL and Q-TWiST among patients randomised to adjuvant dose-intensive epirubicin and cyclophosphamide administered with filgrastim and progenitor cell support (DI-EC) or standard-dose anthracycline-based chemotherapy (SD-CT). We estimated the duration of chemotherapy toxicity (TOX), time without disease symptoms and toxicity (TWiST), and time following relapse (REL). Patients scored QL indicators. Mean durations for the three transition times were weighted with patient reported utilities to obtain mean Q-TWiST. Patients receiving DI-EC reported worse QL during TOX, especially treatment burden (month 3: P<0.01), but a faster recovery 3 months following chemotherapy than patients receiving SD-CT, for example, less coping effort (P<0.01). Average Q-TWiST was 1.8 months longer for patients receiving DI-EC (95% CI, -2.5 to 6.1). Q-TWiST favoured DI-EC for most values of utilities attached to TOX and REL. Despite greater initial toxicity, quality-adjusted survival was similar or better with dose-intensive treatment as compared to standard treatment. Thus, QL considerations should not be prohibitive if future intensive therapies show superior efficacy.British Journal of Cancer (2008) 98, 25-33. doi:10.1038/sj.bjc.6604092 www.bjcancer.com Published online 27 November 2007.

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Publishing Authors By Initials

J Bernhard,D Zahrieh,JJ Zhang,G Martinelli,R Basser,C ,JF Forbes,S Aebi,W Yeo,B ,MD Green,M Colleoni,RD Gelber,M Castiglione-Gertsch,KN Price,A Goldhirsch,AS Coates,J Bernhard,D Zahrieh,JJ Zhang,G Martinelli,R Basser,C Hürny,JF Forbes,S Aebi,W Yeo,B Thürlimann,MD Green,M Colleoni,RD Gelber,M Castiglione-Gertsch,KN Price,A Goldhirsch,AS Coates, ,J Bernhard,D Zahrieh,JJ Zhang,G Martinelli,R Basser,C ,JF Forbes,S Aebi,W Yeo,B ,MD Green,M Colleoni,RD Gelber,M Castiglione-Gertsch,KN Price,A Goldhirsch,AS Coates, ,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: British journal of cancer

VOLUME: 98

Page Numbers: 25-33

Journal Abbreviation: Br. J. Cancer

ISSN: 0007-0920

DAY: 27

MONTH: 11

YEAR: 2007

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 370635

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.

AFFILIATION: [1] 1IBCSG Coordinating Center, Effingerstrasse 40, Bern 3008, Switzerland [2] 2Department of Medical Oncology, Inselspital, Bern, Switzerland.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Quality of life and quality-adjusted survival Q-TWiST in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer Related Publications

• 16-Aza-ent-beyerane and 16-Aza-ent-trachylobane: potent mechanism-based inhibitors of recombinant ent-kaurene synthase from Arabidopsis thaliana.
• A new time-scale for ray-finned fish evolution.
• Alkaline iron(III) reduction by a novel alkaliphilic, halotolerant, Bacillus sp. isolated from salt flat sediments of Soap Lake.
• Association between reproductive factors and breast cancer survival in younger women.
• Carbonylation of Epoxides to Substituted 3-Hydroxy-delta-Lactones.
• Factors associated with advanced disease stage at diagnosis in a population-based study of patients with newly diagnosed breast cancer.
• General and abdominal obesity and survival among young women with breast cancer.
• High-activity, single-site catalysts for the alternating copolymerization of CO2 and propylene oxide.
• Implementation and evaluation of an HIV/STD intervention in Peru.
• Interception of the enzymatic conversion of farnesyl diphosphate to 5-epi-aristolochene by using a fluoro substrate analogue: 1-fluorogermacrene A from (2E,6Z)-6-fluorofarnesyl diphosphate.
• Jejuno-gastric intussusception.
• Levator ani muscle and connective tissue changes associated with pelvic organ prolapse, parity, and aging in the squirrel monkey: a histologic study.
• Main drainage in relation to housing development.
• Oral contraceptives and survival in breast cancer patients aged 20 to 54 years.
• Pain and the surgeon.
• Preliminary neutron and ultrahigh-resolution X-ray diffraction studies of the aspartic proteinase endothiapepsin cocrystallized with a gem-diol inhibitor.
• Prevalence of bacterial vaginosis among young women in low-income populations of coastal Peru.
• Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
• Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.
• Quantifying ammonia emissions from a cattle feedlot using a dispersion model.
• Recreational physical activity and survival among young women with breast cancer.
• Silver Medal Recipient 2007 - DR DUDLEY HILL.
• Surgery in ulcerative colitis.
• Synthesis of beta-lactones: a highly active and selective catalyst for epoxide carbonylation.
• The CARI guidelines. Calcineurin inhibitors in renal transplantation: nephrotoxicity and calcineurin inhibitors.
• The Dioxanone Approach to (2S,3R)-2-C-Methylerythritol 4-Phosphate and 2,4-Cyclodiphosphate, and Various MEP Analogues.
• The chemistry of phosphorus insecticides.
• Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients.
• ent-Beyerane diterpenoids from the heartwood of Excoecaria parvifolia.
• p53 and Mdm2: not all cells are equal.